Target intelligence / Profile preview

Rapidly Dividing Immune Cells (N/A)

Target
N/A
Molecular classification
Cell population, Immune cells, Lymphocytes
01

Overview

Rapidly dividing immune cells are primarily activated lymphocytes (T and B cells) undergoing clonal expansion in response to antigen stimulation. This rapid proliferation is essential for mounting an effective adaptive immune response. Key mechanisms involve upregulation of transcription factors like c-Myc, driving cell cycle progression and metabolic changes necessary for rapid division. While vital for pathogen clearance and immunological memory, uncontrolled proliferation can lead to autoimmunity or malignancy. Targeting these cells is relevant for immunosuppression, autoimmune disease therapy, and cancer immunotherapy modulation.

Other names
Activated LymphocytesProliferating Immune CellsClonally Expanded LymphocytesEffector T CellsPlasma CellsProliferating B Cells
02

Mechanism of action

Varies depending on the specific drug and targeted pathway. Examples include: inhibition of T cell activation, inhibition of DNA synthesis, and induction of cell death.

03

Biological functions

Immune responseAdaptive immunityAntigen recognitionCell proliferationCytokine productionAntibody productionCytotoxicity
04

Disease associations

InfectionAutoimmunityCancer (immune surveillance/response)Transplant rejection
05

Safety considerations

Opportunistic infections (due to immunosuppression)Increased risk of malignancy (due to impaired immune surveillance)Cytokine release syndromeAutoimmunity (paradoxical effects in some cases)Off-target effects on other cell types
06

Interacting drugs

Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Methotrexate)

3 more in the full profile.

07

Biomarkers

Ki67 (proliferation marker)CD25 (IL-2 receptor alpha chain)c-Myc expressionTCR/BCR clonalityCytokine levels (e.g., IL-2, IFN-gamma)Antibody titers

Beyond the preview

Go deeper on Rapidly Dividing Immune Cells (N/A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapidly Dividing Immune Cells (N/A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call